Development of proprietary medicines

Adamed Discovery – Where Polish Innovation Begins

At our state-of-the-art Research and Development Center in Kajetany, the multidisciplinary team at Adamed Discovery is dedicated to developing new molecules and future therapies. Leveraging advanced technologies—including cutting-edge laboratory techniques, machine learning, and artificial intelligence—our scientists are actively seeking candidates for original drugs in oncology and neuropsychiatry.

We have been at the forefront of original pharmaceutical research in Poland, establishing a robust foundation that has facilitated the development of novel molecules domestically and set the stage for continued innovation in the field. To advance these objectives, we have entered numerous partnerships with leading academic institutions and actively engaged the broader scientific community in our drug discovery initiatives.

With over 20 years of experience and expertise, our team excels in:

  1. Designing and optimizing methods for obtaining both small molecules and biologics,
  2. Conducting advanced analytics and structural characterization,
  3. Verifying functionality and efficacy at the molecular level through cellular assays,
  4. Assessing the potential of these molecules to progress through subsequent development stages by determining their pharmacokinetic and pharmacodynamic parameters, as well as their safety profiles in toxicological studies.

In our work on the development of new molecules, we use advanced mathematical tools and in silico modeling, i.e. computer simulations that allow us to predict their properties and operation. We also use machine learning and AI algorithms to help analyze data and design and improve molecules with therapeutic potential.

Currently, our activities are centered on five research programs: three oncology projects, two neuropsychiatric drug development projects, and exploratory initiatives aimed at evaluating new concepts.

Among our accomplishments, we have identified and progressed two drug candidate molecules into clinical development. The first is a recombinant fusion variant of the TRAIL/Apo2L protein, designed by our scientists as a candidate for the treatment of solid tumors. In 2025, we initiated its phase I clinical trial in Poland, in collaboration with national partners. The second molecule is a selective inhibitor of MDM2 and p53 activity and has exhibited anticancer properties in preclinical models of sarcomas, lymphomas, and leukemias. This initiative is presently underway at clinical trial centers in the United States through our collaboration with Lamassu Biotech.

Strategic partnerships and licensing agreements are integral to our drug development strategy. In the area of CNS drug research, we signed a license agreement with Acadia Pharmaceuticals in 2020. We remain actively engaged in seeking new partners for future collaborations.

Pipeline

Discovery Lead optimisation IND - enabling studies Phase I

Innovation Department Labs & Teams

Data Modelling & Analysis Lab
Biotechnology Lab
Proteomics Lab
Cell Biology Lab
Laboratory Animals Team
Preclinical Development Team
CNS Team
Data Modelling & Analysis Lab

The Lab possesses infrastructure and software for the modelling, visualisation, and comparative analysis of spatial structures which are molecular binding sites for newly developed medicines, effector molecules, and their mutual interactions. The team also has expertise in high-throughput compound analysis and protein sequencing. The Lab also develops Adamed’s own research algorithms and database software for the collection, analysis, and processing of results obtained through experiments.

Biotechnology Lab

The Biotechnology Lab is responsible for developing protein production processes as part of Adamed’s innovative research programmes. The Lab’s tasks include optimisation of the following protein manufacturing stages: designing DNA constructs coding the target molecules, selection of bacterial strains and expression vectors, establishing the optimal conditions for expression, and scaling the manufacturing process.

Proteomics Lab

Content: The main activities of the Proteomics Lab include the design and implementation of purification methods for recombinant proteins with therapeutic potential, analytics of proteins and bioconjugates, and providing their exact characteristics. An important part of the Lab’s work is participation in studies of molecular mechanisms of action and molecule pharmacology to prepare the molecules for advanced stages of the development process as drug candidates.

Cell Biology Lab

Content: Eukaryotic cell cultures are routinely used in biotechnological and toxicological protocols. Cells cultivated in appropriate conditions can be used for screening newly created molecules, thereby significantly reducing the number of animal tests. At the early stages of the drug development process, properly planned experiments using cell lines enable investigators to answer many questions about the mechanism of action, initial toxicological activity, or interactions with other substances.

Laboratory Animals Team

The Laboratory Animals Team is responsible for conducting research studies to acquire the knowledge necessary for the development of drug candidates. The Team follows national and European guidelines and is committed to maintaining high ethical, hygienic, and methodological standards in the rodent vivarium. Ensuring the welfare of laboratory animals based on the 3R principle and close collaboration with the Research Department, the Preclinical Development Team, and external expert organisations allow the Team to accurately conduct studies in order to ensure highly reliable results.

Preclinical Development Team

The Preclinical Development Team coordinates the company’s activities in the area of preclinical studies of selected drug candidates. With its vast skills and experience, the Team can efficiently assess if molecules are ready for phase 1 clinical trials (known as first-in-human, FIH) and provide significant support for finished value-added dosage forms, allowing Adamed to obtain regulatory approval for bringing new medicines to the Polish and international markets.

CNS Team

Content: The CNS Team is responsible for all research activities carried out by the Innovation Department in the area of central nervous system disorders. The Team’s tasks include the selection of clinical indications and biological targets, designing new chemical molecules with therapeutic potential, and providing broad in vitro and in vivo pharmacological characteristics.

Structure

Our expertise